FiercePharmaAsia—Takeda's rare disease decline; Astellas-Pandion diabetes deal; I-Mab's Nasdaq IPO

Asia Map
Takeda, Astellas, I-Mab and more made our news this week. (Google)

Takeda's rare disease business shrank in the previous two quarters, thanks to competition facing Shire's legacy hemophilia drugs and a surprise U.S. recall of Natpara. Astellas is paying Pandion Therapeutics $45 million upfront for a collaboration on Type 1 diabetes. And as Chinese biotechs rush to Hong Kong for their initial public offerings after a listing rule tweak, Shanghai-based immunotherapy player I-Mab Biopharma has chosen Nasdaq instead, aiming to raise up to $100 million. And more.

1. Hemophilia rivalry eats away at post-Shire Takeda—and its Natpara recall bites, too

Takeda’s rare disease business is suffering. In the first half of Takeda’s fiscal year ended in September, the unit’s underlying revenue dropped 11%. Due to competitive pressure—likely from Roche’s Hemlibra—sales of Advate, once Shire’s flagship hemophilia A drug, plummeted 16% during the period to JPY 83.2 billion ($766 million). And the U.S. recall of hypoparathyroidism drug Natpara further dragged down its performance.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

2. Astellas, Pandion team up on Type 1 diabetes bispecifics in deal worth up to $795M

Astellas is teaming up with Pandion Therapeutics to work on bispecific drugs for Type 1 diabetes and other autoimmune diseases of the pancreas in a deal worth up to $795 million. Pandion will use its modular immune effector and tissue tether tech to discover and design candidates, while Astellas will take care of preclinical and clinical development and commercialization.

3. Chinese immunotherapy biotech I-Mab files for $100M Nasdaq IPO (SEC filing)

I-Mab Biopharma has filed to list on Nasdaq, planning to raise up to $100 million. The Shanghai-based company is focused on developing biologics in immuno-oncology and autoimmune diseases. Last year, it raised a massive $220 million in series C. The company’s lead drug, TJ202/MOR202, an anti-CD38 antibody it licensed in China from MorphoSys, is in phase 3 trial for multiple myeloma there.

4. As Sanofi preps to leave Bangladesh, workers there plan a hunger strike: report

Sanofi has decided to leave Bangladesh by selling its 54.64% stake in the local operation. It intends to “negotiate a collective employment guarantee clause for at least twelve months” with the buyer, the French pharma said. But the employees said they are not convinced. Pointing to GlaxoSmithKline’s recent deal to exit the country, the Sanofi Bangladesh workers are asking for compensation packages.

5. WuXi Biologics doubles down on Ireland, will build vaccine plant there

After selecting Ireland for its first manufacturing site outside of China, WuXi Biologics has won approval to build a 15,520-square-meter vaccine facility right next to where it’s building a biologics facility in Dundalk, Ireland. CEO Chris Chen said the project was for a single, as yet unnamed client.

6. Local immunotherapy player SinoMab eyes $223M Hong Kong IPO (Caixin story)

SinoMab BioScience plans to raise as much as HK$1.75 billion ($223 million) in a Hong Kong IPO. Chinese pharma giant Yunnan Baiyao Group pledged to subscribe for $50 million. The Hong Kong-based clinical-stage biotech focuses on immunological diseases. Its lead drug, SM03, is in late-stage studies for rheumatoid arthritis.

7. Singapore skin diagnostics company Sequential launches

Singapore skin diagnostics company Sequential is launching with a technology that uses the Asian Skin Microbiome Project’s data to give a picture of the genetics and microbiome that affect a person’s skin.

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.